Virtus ETF Advisers LLC Recursion Pharmaceuticals, Inc. Transaction History

Virtus ETF Advisers LLC

$206 Million
Q3 2024

A detailed history of Virtus ETF Advisers LLC transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 9,763 shares of RXRX stock, worth $69,512. This represents 0.03% of its overall portfolio holdings.

Number of Shares

9,763

Previous 9,590 1.8%

Holding current value

$69,512

Previous $71,000 9.86%

% of portfolio

0.03%

Previous 0.04%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$5.92 - $8.6 $1,024 - $1,487	173 Added 1.8%	9,763 $64,000
Q2 2024 Aug 14, 2024	BUY	$7.35 - $10.05 $3,652 - $4,994	497 Added 5.47%	9,590 $71,000
Q1 2024 May 15, 2024	SELL	$9.13 - $15.52 $5,678 - $9,653	-622 Reduced 6.4%	9,093 $90,000
Q4 2023 Feb 15, 2024	SELL	$5.09 - $10.79 $1,613 - $3,420	-317 Reduced 3.16%	9,715 $95,000
Q3 2023 Nov 07, 2023	SELL	$6.59 - $15.86 $6,563 - $15,796	-996 Reduced 9.03%	10,032 $76,000
Q2 2023 Aug 14, 2023	SELL	$4.56 - $9.94 $259 - $566	-57 Reduced 0.51%	11,028 $82,000
Q1 2023 May 15, 2023	SELL	$6.42 - $9.64 $27,329 - $41,037	-4,257 Reduced 27.75%	11,085 $73,000
Q4 2022 Feb 14, 2023	SELL	$7.16 - $12.7 $10,775 - $19,113	-1,505 Reduced 8.93%	15,342 $118,000
Q3 2022 Nov 14, 2022	BUY	$7.83 - $13.6 $947 - $1,645	121 Added 0.72%	16,847 $179,000
Q2 2022 Aug 12, 2022	BUY	$5.04 - $9.26 $42,361 - $77,830	8,405 Added 101.01%	16,726 $136,000
Q1 2022 May 16, 2022	SELL	$6.16 - $18.03 $3,080 - $9,015	-500 Reduced 5.67%	8,321 $60,000
Q4 2021 Feb 14, 2022	BUY	$16.14 - $21.86 $142,370 - $192,827	8,821 New	8,821 $151,000

Others Institutions Holding RXRX

# of Institutions

287

Shares Held

242M

Call Options Held

1.35M

Put Options Held

2.32M

View Full List

About RECURSION PHARMACEUTICALS, INC.

Ticker RXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 180,480,000
Market Cap $1.29B
Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...

More about RXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.

Account

Virtus ETF Advisers LLC Recursion Pharmaceuticals, Inc. Transaction History